• IMA sites
  • IMAJ services
  • IMA journals
  • Follow us
  • Alternate Text Alternate Text
עמוד בית
Sat, 18.05.24

Search results


January 2011
S. Badarny, H. Rawashdeh, J. Meer, S. Abed and G. Habib
Background: Local corticosteroid injection for the treatment of carpal tunnel syndrome, using the classic method, is usually associated with improvement in different electrophysiologic parameters of the median nerve. However, there was no correlation between the clinical response and these electrophysiological parameters. 

Objectives: To evaluate the effect of our novel approach of LCI[1] for the treatment of CTS[2] on repeated electrophysiologic studies of the median nerve.

Methods: Patients with symptomatic CTS with duration of symptoms of less than 1 year were offered a LCI of 12 mg methylprednisolone acetate using a novel approach and asked to repeat the EP study one month later. Pearson correlation test was used to correlate between the difference of similar electrophysiological parameters and duration of favorable clinical response and also between the differences among themselves.

Results: Thirteen patients completed the study and 25 hands were injected. Improvement in median distal sensory and motor latency was noted in 61% and 75% of the hands respectively. There was no correlation between duration of clinical response and the differences of either the distal latency (sensory or motor) or the amplitude. There was also no correlation between the differences of motor median distal latency and sensory median distal latency.

Conclusions: LCI at the carpal tunnel using our approach is also associated with favorable electrophysiologic results similar to what had been reported using the classic approach.
July 2008
S. Badarny, Z. Susel and S. Honigman

Background: Long-term therapy with botulinum toxin is sometimes associated with therapy failure following repeated injections of the neurotoxin, presumably due to specific antibody production. Primary therapy failure with botulinum toxin is less common and poorly understood.

Objectives: To examine the effectiveness of the botulinum neurotoxin Dysport® in patients with blepharospasm and hemifacial spasm after primary or secondary failure with Botox® treatments. .

Methods: In this case series study, eight patients with blepharospasm and hemifacial spasm who experienced primary or secondary therapy failure with Botox were treated with Dysport. In order to render an equivalent Dysport dose, a conversion ratio of 1:3 to 1:4 Botox /Dysport was used.

Results: Two patients, one with blepharospasm and the other with hemifacial spasm, who showed primary therapeutic failure with Botox showed good response to Dysport treatments. One patient with tardive blepharospasm did not respond to either drug. Two patients with blepharospasm and three patients with hemifacial spasm who experienced Botox secondary therapy failure responded well to Dysport treatments.

Conclusions: Botox and Dysport are both serotype A botulinum toxins but carry different characteristics of biological activity. These differences possibly account for the favorable therapeutic response to Dysport in patients with hemifacial spasm or blepharospasm following failure with Botox treatments.
 

February 2007
Y. Har Shai, I. Metanes, S. Badarny, P. Cuzin, T. Gil, S. Mayblum, B. Aman, D. Labbé
Legal Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal or medical advice on any matter.
The IMA is not responsible for and expressly disclaims liability for damages of any kind arising from the use of or reliance on information contained within the site.
© All rights to information on this site are reserved and are the property of the Israeli Medical Association. Privacy policy

2 Twin Towers, 35 Jabotinsky, POB 4292, Ramat Gan 5251108 Israel